A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma: Clinical article

Journal of Neurosurgery

Volumn 116, Issue 2, 2012, Pages 341-345

  Narayana, Ashwatha ^a   Gruber, Deborah ^a   Kunnakkat, Saroj ^a   Golfinos, John G ^a   Parker, Erik ^a   Raza, Shahzad ^a   Zagzag, David ^a   Eagan, Patricia ^a,b   Gruber, Michael L ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b OVERLOOK HOSPITAL   (United States)

Author keywords

Bevacizumab; Glioblastoma; Oncology; Radiation therapy; Temozolomide

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; VASCULOTROPIN;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84856806386     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2011.9.JNS11656     Document Type: Article

References (25)

1. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A: Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19:163-170, 2009
2. Duda DG, Jain RK, Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042, 2007 (Pubitemid 47492947)
3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
5. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16: 2443-2449, 2010
6. Gruber ML, Raza S, Gruber D, Narayana A: Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression- free survival, overall survival, and toxicity. ASCO Meeting Abstracts 27:2017, 2009
7. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73: 1200-1206, 2009
8. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001
9. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007 (Pubitemid 47093931)
10. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
11. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148, 2011
12. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399-1405, 2003 (Pubitemid 36418393)
13. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al: Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
14. Miyagami M, Katayama Y: Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 38:36-42, 2005 (Pubitemid 351543890)
15. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, et al: Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383-389, 2008
16. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. Clinical article. J Neurosurg 110:173-180, 2009
17. Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, Knopp E, et al: Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys [epub ahead of print], 2010
18. Narayana A, Recht L, Gutin PH: Central Nervous System Tumors, in Hoppe RT, Philips TL, Roach M (eds): Textbook of Radiation Oncology. Philadelphia: Saunders, 2010, pp 421-432
19. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217-1222, 2009
20. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
21. Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, et al: Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neurooncol 10:690-699, 2008
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005 (Pubitemid 40349501)
23. Vredenburgh JJ, Desjardins A, Herndon JE Jr, Dowell JM, Reardon DA, Quinn JA, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
24. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004 (Pubitemid 38524883)
25. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, et al: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80:837-849, 2000 (Pubitemid 30421801)